Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 1, 2011, Pages 86-94

  Adhikari, Neeta ^a   Basi, David L ^b   Carlson, Marjorie ^a   Mariash, Ami ^a   Hong, Zhigang ^a,c   Lehman, Ute ^a   Mullegama, Sureni ^a   Weir, Edward K ^a   Hall, Jennifer L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Developmental Surgical Science   (United States)

^c Affairs Medical Center   (United States)

Author keywords

glucose; Glut1; haptoglobin; hypertrophy; macrophage; neutrophil; phosphoSMAD2 3; vascular smooth muscle

Indexed keywords

DEOXYGLUCOSE; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUTATHIONE; HAPTOGLOBIN; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD VESSEL FUNCTION; BLOOD VESSEL INJURY; DIET RESTRICTION; FATTY ACID BLOOD LEVEL; FEMALE; GENE OVEREXPRESSION; GLUCOSE TRANSPORT; HYPERTROPHY; IMMUNOFLUORESCENCE; INFLAMMATION; INSULIN BLOOD LEVEL; ISOTOPE LABELING; MOUSE; NEUTROPHIL; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SMOOTH MUSCLE; STAINING; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; BLOOD GLUCOSE; CELLS, CULTURED; CHEMOKINE CCL2; DEOXYGLUCOSE; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; FEMORAL ARTERY; GLUCOSE TRANSPORTER TYPE 1; GLUTATHIONE; HAPTOGLOBINS; HUMANS; HYPERTROPHY; INFLAMMATION; INSULIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEUTROPHIL INFILTRATION; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; SMAD2 PROTEIN; SMAD3 PROTEIN; UP-REGULATION; VASOCONSTRICTION;

EID: 78650918683     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.215004     Document Type: Article

References (56)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
2. Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis. 2000; 148:159-169.
3. Hashim S, Li Y, Anand-Srivastava MB. G protein-linked cell signaling and cardiovascular functions in diabetes/hyperglycemia. Cell Biochem Biophys. 2006;44:51-64.
4. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003; 348:2294-2303.
5. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH. Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39:1116-1124. (Pubitemid 20263324)
6. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996;313:779-784.
7. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 362:800-811.
8. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004;27:530-537. (Pubitemid 38174083)
9. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbuhl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27-38.
10. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431.
11. Li L, Miano JM, Cserjesi P, Olson EN. Sm22-, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res. 1996;78:188-195.
12. Hall JL, Grindle S, Han X, Fermin D, Park S, Chen Y, Bache RJ, Mariash A, Guan Z, Ormaza S, Thompson J, Graziano J, de Sam Lazaro SE, Pan S, Simari RD, Miller LW. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004;17: 283-291.
13. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A role for the-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res. 2002;90:340-347.
14. Hall JL, Henderson J, Hernandez LA, Kellerman LA, Stanley WC. Hyperglycemia results in an increase in myocardial interstitial glucose and glucose uptake during ischemia. Metabolism. 1996;45:542-549.
15. Hall JL, Lopaschuk GD, Barr A, Bringas J, Pizzurro RD, Stanley WC. Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels. Cardiovasc Res. 1996;32:879-885.
16. Hall JL, Matter CM, Wang X, Gibbons GH. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase c-dependent pathway. Circ Res. 2000;87:574-580.
17. Hall JL, Stanley WC, Lopaschuk GD, Wisneski JA, Pizzurro RD, Hamilton CD, McCormack JG. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol. 1996;271:H2320-H2329.
18. Ray JL, Leach R, Herbert JM, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 2001;23: 185-188.
19. Hong Z, Smith AJ, Archer SL, Wu XC, Nelson DP, Peterson D, Johnson G, Weir EK. Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation. 2005;112:1494-1499.
20. Basi DL, Adhikari N, Mariash A, Li Q, Kao E, Mullegama SV, Hall JL. Femoral artery neointimal hyperplasia is reduced after wire injury in Ref-1-/- mice. Am J Physiol Heart Circ Physiol. 2007;292:H516-H521.
21. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000;32:2097-2104.
22. Abboud K, Bassila JC, Ghali-Ghoul R, Sabra R. Temporal changes in vascular reactivity in early diabetes mellitus in rats: role of changes in endothelial factors and in phosphodiesterase activity. Am J Physiol Heart Circ Physiol. 2009;297:H836-H845.
23. Ajay M, Achike FI, Mustafa MR. Modulation of vascular reactivity in normal, hypertensive and diabetic rat aortae by a non-antioxidant flavonoid. Pharmacol Res. 2007;55:385-391.
24. Zeydanli EN, Turan B. Omega-3e treatment regulates matrix metalloproteinases and prevents vascular reactivity alterations in diabetic rat aorta. Can J Physiol Pharmacol. 2009;87:1063-1073.
25. Lemarie CA, Tharaux PL, Lehoux S. Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol. 2010;48:433-439.
26. Hinton RB, Adelman-Brown J, Witt S, Krishnamurthy VK, Osinska H, Sakthivel B, James JF, Li DY, Narmoneva DA, Mecham RP, Benson DW. Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circ Res. 2010; 107:549-557.
27. Hocking DC, Titus PA, Sumagin R, Sarelius IH. Extracellular matrix fibronectin mechanically couples skeletal muscle contraction with local vasodilation. Circ Res. 2008;102:372-379.
28. Horiguchi M, Inoue T, Ohbayashi T, Hirai M, Noda K, Marmorstein LY, Yabe D, Takagi K, Akama TO, Kita T, Kimura T, Nakamura T. Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase. Proc Natl Acad Sci USA. 2009;106:19029-19034.
29. Kwan CY, Wang RR, Beazley JS, Lee RM. Alterations of elastin and elastase-like activities in aortae of diabetic rats. Biochim Biophys Acta. 1988;967:322-325.
30. McDonald TO, Gerrity RG, Jen C, Chen HJ, Wark K, Wight TN, Chait A, O'Brien KD. Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis. J Histochem Cytochem. 2007;55: 1149-1157.
31. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2007;27:134-140.
32. McMillan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism. 1989;38:1042-1046.
33. Van Campenhout A, Van Campenhout C, Lagrou AR, Abrams P, Moorkens G, Van Gaal L, Manuel-y-Keenoy B. Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status. Diabetes Metab Res Rev. 2006;22:444-454.
34. Nosslin BF, Nyman M. Haptoglobin determination in diagnosis of haemolytic diseases. Lancet. 1958;1:1000-1001.
35. Nyman M. Serum hatoglobin: methodological and clinical studies. Scand J Clin Lab Invest. 1959;11:1-169.
36. Brunetti ND, Correale M, Pellegrino PL, Cuculo A, Biase MD. Acute phase proteins in patients with acute coronary syndrome: correlations with diagnosis, clinical features, and angiographic findings. Eur J Intern Med. 2007;18:109-117.
37. Gottlieb A, Wisch N, Ross J. Familial hypohaptoglobinemia. A genetically determined trait segregating from glucose-6-phosphate dehydrogenase deficiency. Blood. 1963;21:129-140.
38. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes. 2001;50: 851-860.
39. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucoseinduced nuclear factor-b activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol. 2002;13: 894-902.
40. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006;17:1362-1372.
41. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271.
42. Booth G, Stalker TJ, Lefer AM, Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol Endocrinol Metab. 2001;280:E848-E856.
43. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, Herrath MG, Chait A, Bornfeldt KE. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 2004;114:659-668.
44. Johansson F, Kramer F, Barnhart S, Kanter JE, Vaisar T, Merrill RD, Geng L, Oka K, Chan L, Chait A, Heinecke JW, Bornfeldt KE. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci USA. 2008;105:2082-2087.
45. Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, San H, Childs R, Kovacic JC, Boehm M. p21Cip1 modulates arterial wound repair through the stromal cell- derived factor-1/CXCR4 axis in mice. J Clin Invest. 2008;118:2050-2061.
46. Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G, Vlassara H. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009;175:1722-1732.
47. Owens GK, Geisterfer AA, Yang YW, Komoriya A. Transforming growth factor-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol. 1988;107:771-780.
48. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. Hyperplasia. Autocrine transforming growth factor-1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90: 456-461.
49. Wu LD, R. Essential role of TGF-signaling in glucose-induced cell hypertrophy. Dev Cell. 2009;17:35-48.
50. Mahimainathan L, Das F, Venkatesan B, Choudhury GG. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes. 2006;55:2115-2125.
51. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest. 1996;97:1767-1773.
52. Nishina PM, Naggert JK, Verstuyft J, Paigen B. Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism. 1994;43:554-558.
53. Harrington J, Pena AS, Gent R, Hirte C, Couper J. Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. J Pediatr. 156:237-241.
54. Larsen JR, Brekke M, Bergengen L, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Mean HbA1c over 18 years predicts carotid intima media thickness in women with type 1 diabetes. Diabetologia. 2005;48: 776-779.
55. Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LE, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes. 1996;45:1253-1258.
56. Hall JL, Chatham JC, Eldar-Finkelman H, Gibbons GH. Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis: role of GSK3-. Diabetes. 2001;50:1171-1179.